Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study

Schommers, Philipp; Gillor, Daniel; Hentrich, Marcus; Wyen, Christoph; Wolf, Timo; Oette, Mark; Zoufaly, Alexander; Wasmuth, Jan‐Christian; Bogner, Johannes R.; Müller, Marcus; Eßer, Stefan; Schleicher, Alisa; Jensen, Bjöern; Stoehr, Albrecht; Behrens, Georg M. N.; Schultze, Alexander; Siehl, Jan; Thoden, Jan; Taylor, Ninon; Hoffmann, Christian

doi:10.3324/haematol.2017.180893

Cited by 31 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… AIDS acquired immune deficiency syndrome, ART antiretroviral therapy, EBV Epstein Barr virus, HHV human herpes virus, HIV human immunodeficiency virus, IPI international prognostic index. Adapted from [ 12 – 14 , 15 •] …”

Section: Introductionmentioning

confidence: 99%

The Changing Landscape of Lymphoma Associated with HIV Infection

Hübel

2020

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review Cancer remains a major cause of morbidity and mortality in HIV-infected individuals, with aggressive non-Hodgkin’s lymphoma as the most frequent one. However, the introduction of modern antiretroviral therapy (ART) drastically improved treatment options and prognosis in HIV-associated lymphomas. This review summarized the current treatment landscape and future challenges in HIV-positive patients with non-Hodgkin’s and Hodgkin’s lymphoma. Recent Findings Selecting the appropriate therapy for the individual patient, diffuse-large B cell lymphoma, Burkitt’s lymphoma, and Hodgkin’s disease may be curable diseases. In contrast, the prognosis of plasmablastic lymphoma and primary effusion lymphoma remain poor. New treatment approaches, as targeted therapies or CAR T cell therapy, may broaden the therapeutic armamentarium. Summary The continuous application of ART is mandatory for successful treatment. The choice of lymphoma therapy may follow the recommendations for HIV-negative patients, but prospective trials in HIV-lymphoma are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

The Changing Landscape of Lymphoma Associated with HIV Infection

Hübel

2020

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“… 31 Moreover, the five-year survival rate of patients who achieve complete remission through first-line chemotherapy may be as high as 87.8%. 32 Whether to undertake chemotherapy has been recognized as an independent prognostic factor for lymphoma, even in patients positive for HIV infection. However, there have been few studies on the survival analysis after chemotherapy, and there are many confounding prognostic factors that are biased and difficult to evaluate.…”

Section: Discussionmentioning

confidence: 99%

The Value of Nutritional Status in the Prognostic Analysis of Patients with AIDS-Related Lymphoma

Sun

Qian

Luo

et al. 2021

IDR

View full text Add to dashboard Cite

Objective Many studies have suggested that indexes of nutritional status, such as body mass index (BMI), serum albumin (ALB), serum pre-albumin (PA), and hemoglobin, may be used as risk factors for the prognosis of HIV or lymphoma. Therefore, this study aimed to retrospectively analyze and explore the value of nutritional status in the prognostic assessment of patients with AIDS-related lymphoma (ARL). Methods In this retrospective study, the clinical data of 69 patients with ARL were collected. All patients had a definite diagnosis of non-Hodgkin lymphoma by pathological examination and met the requirements of the Hematopoietic and Lymphocytic Tissue Tumor Classification (2016) established by the World Health Organization. Patients who did not receive standard chemotherapy, those with incomplete medical records, and those with an unclear pathological diagnosis were excluded. The patients were divided into two groups (survival and death) according to the prognostic outcome, and their clinical characteristics and prognoses were discussed by relevant statistical methods. Results During the three-year follow-up period, 20 (28.99%) patients died, and 49 (71.01%) survived. The one-year cumulative survival rate was 78.26%. A univariate analysis found that the prognosis was associated with the International Prognostic Index (IPI) score, BMI, ALB, PA, and CD4 T lymphocyte count. The Cox risk proportional regression analysis showed that the IPI score, BMI, and PA were the independent risk factors for survival; their combination had a greater ability to forecast the clinical outcome (area under the curve = 0.874, P < 0.001). Conclusion In this study, at the time of the visit, the patients with ARL tended to be in the advanced stages of disease and, therefore, at high risk of mortality. Therefore, their nutritional status might be of great value to the prognostic assessment. The combination of BMI, PA, and IPI scores could be used for risk stratification and better screening of high-risk patients.

show abstract

“…Adult HIV‐1‐infected patients with biopsy‐ or cytologically proven malignant lymphoma diagnosed at 34 participating centres in Germany and Austria from January 2005 to November 2018 were included in the study 9 . Ethics approval was obtained from the ethics committees of the University of Cologne, and written informed consent was given by each participating patient.…”

Section: Id Ipi Solid Variant Localization Pel* Hhv8+ Hhv8 Cop/ml† Pel Ebv+‡ First‐line Therapy Best Response Ttr (Mo) Localization Of Rementioning

confidence: 99%